Global Anti-depression Drugs Market - 2024-2031

Global Anti-depression Drugs Market - 2024-2031

The global anti-depression drugs market reached US$ 15.81 billion in 2023 and is expected to reach US$ 22.10 billion by 2031, growing at a CAGR of 4.3% during the forecast period 2024-2031.

Antidepressant drugs work by increasing levels of chemicals in the brain called neurotransmitters such as serotonin and noradrenaline that are linked to mood and emotion. Antidepressants are used to treat major depressive disorder, anxiety disorders, premenstrual dysphoric disorder (PMDD), and bipolar depression.

There is a growing incidence of depression disorders globally. This increasing incidence increases the demand for anti-depression drugs. For instance, according to the World Health Organization report in 2023, depression affects approximately 3.8% of the population, including 5% of adults (4% among men and 6% among women) and 5.7% of individuals over the age of 60. Approximately 280 million individuals have depression globally.

Market Dynamics: Drivers & Restraints

Increasing research and developments for antidepressant drugs

The global market for anti-depression drugs has grown significantly as a result of recent research and innovations. With the rising incidence of depression disorders, several companies, and research institutes are conducting a large number of studies. Depression is typically diagnosed based on medical history, and clinical and imaging data.

Advanced research and innovations in the treatment of major depressive disorder could contribute to the anti-depression drugs market. The increasing development of anti-depression drugs expands the availability of these drugs. For example, in August 2023, Novartis AG announced that the medication Onfasprodil is in clinical development Phase II for Treatment Resistant Depression. Onfasprodil (MIJ-821) is used to treat depression that is resistant to other treatments as well as major depressive disorder.

Side effects associated with treatment drugs

Antidepressant medicines are effective in treating depression, but they can also cause unpleasant side effects such as nausea, weight gain, sexual dysfunction, and, in a small percentage of patients, an increased risk of suicidal thoughts. The requirement for careful monitoring and evaluation of these safety risks, particularly in certain patient categories, may limit antidepressant drug use.

Segment Analysis

The global anti-depression drugs market is segmented based on drug class, depression disorder, route of administration, distribution channel and region.

Drug Class:

Selective Serotonin Reuptake Inhibitors (SSRIs) segment is expected to dominate the anti-depression drugs market share

Selective Serotonin Reuptake Inhibitors (SSRIs) held a major position in the anti-depression drugs market share and are expected to continue throughout the forecast period. SSRIs have been thoroughly researched and proven to be advantageous in treating depression and anxiety disorders, making them a first-line therapeutic option. SSRIs have a lower risk of side effects than other antidepressants, which leads to higher adherence from patients.

Rising clinical trials on the efficacy and their applications are significant factors for the segment growth. A total of 933 clinical trials have been conducted for depression therapies. For example, on July 13, 2023, the University of Minnesota initiated a clinical trial focused on an Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression. This study aims to assess the effectiveness of two adaptive treatment strategies (ATSs) specifically utilizing SSRIs such as Fluoxetine, Escitalopram, Citalopram, Fluvoxamine, or Sertraline.

Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) segment is the fastest growing segment in the anti-depression drugs market share

Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) segment is at the fastest growing pace in the global anti-depression drugs market. SNRIs offer various advantages over other types of anti-depression drugs such as monoamine oxidase inhibitors. SNRIs have comparatively fewer side effects than other drugs which makes individuals prefer these drugs over other type of anti-depression drugs.

Depression Disorder:

Major depressive disorder segment is expected to dominate the Anti-depression Drugs market share

The major depressive disorder segment is expected to hold the dominant position in the anti-depression drugs market share. This is due to the increasing incidence of the condition. A large number of individuals depend on anti-depression drugs to relieve the condition.

For instance, according to a report published by the National Institute of Health in 2023, it is stated that major depressive disorder is a highly prevalent psychiatric disorder. It has a lifetime prevalence of about 5 to 17 percent, with the average being 12 percent. The prevalence rate is almost double in women than in men.

Bipolar depression segment is the fastest-growing segment in the Anti-depression Drugs market share

The bipolar depression segment is emerging as the fastest-growing segment in the anti-depression drugs market. This growth is driven by the growing incidence of bipolar depression and the rising advancements in the diagnostic procedures for the condition.

Geographical Analysis

North America is expected to hold a significant position in the anti-depression drugs market share

North America has retained a significant portion of the antidepressant medications market in recent years, and this trend is expected to continue during the projection period due to factors such as increased FDA approvals and research and development of anti-depression drugs.

A large number of companies are receiving FDA approvals for their new drugs treating depression disorders, which is contributing to the large anti-depression drugs market expansion. For instance, in August 2022, Axsome Therapeutics, Inc. received FDA approval for AUVELITY (dextromethorphan HBr - bupropion HCl) extended-release tablets. This marked AUVELITY as the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist authorized for treating major depressive disorder (MDD) in adults.

Asia-Pacific is growing at the fastest pace in the anti-depression drugs market

Asia-Pacific is experiencing the fastest growth in anti-depression drugs. This is due to the growing incidence of depression disorders and related disorders, and growing awareness among individuals regarding mental health. The region has a large number of pharmaceutical companies which are involved in the production of different drugs including anti-depression drugs.

Competitive Landscape

The major global players in the anti-depression drugs market include Eli Lilly and Company, Viatris Inc., GlaxoSmithKline Plc., Zheijiang Huahai Pharmaceutical Co. Ltd., AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd, Pfizer Inc., Aurobindo Pharma Limited, H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. among others.

Key Developments
• In December 2022, the FDA approved VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for adult patients with MDD, as reported by AbbVie. Cariprazine, marketed as VRAYLAR in the U.S., is also FDA-approved for treating adults experiencing depressive episodes, acute manic episodes, and mixed episodes associated with bipolar I disorder, alongside schizophrenia.
• In July 2024, Johnson & Johnson submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD).

Why Purchase the Report?
• To visualize the global anti-depression drugs market segmentation based on drug class, depression disorder, route of administration, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of anti-depression drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global anti-depression drugs market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.